US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 20:40:47 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
Next:California congressman urges closer consultation with tribes on offshore wind
You may also like
- Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
- International contemporary art fair held in Ankara
- Traditional villages with local characteristics built to develop rural tourism in Hebei
- Chinese President Receives Credentials of 70 Ambassadors
- Julian Assange's five
- Taihang mountains attract visitors as leaves change colors
- Xi Story: A Farmland Visitor and the Vision for China's Food Security
- Understanding Xi's Quotes on Building a Community with a Shared Future for Mankind
- National Television Awards 2024 nominations: Michelle Keegan and Leo Woodall go head